Invesco Biotechnology & Genome ETF (PBE)

Key Metrics

TER 0.59% per year

Distribution policy Distributing

Fund size USD 282 M

Inception date June 23, 2005

Holdings 33

Fund currency USD

Fund domicile US

Provider Invesco

For full official fund details, factsheets, and holdings, visit invesco.com (opens in new tab).

Historical Return

Last updated: Nov 01, 2026

1 Year +37.5% +1.4% Div

3 Years (avg.) +23.8% +1.4% Div

5 Years (avg.) +5.9% +1.4% Div

Risk & Analysis Metrics

Last updated: Nov 01, 2026

Volatility

18.55% 1 Year

19.82% 3 Years

22.21% 5 Years

24.45% 10 Years

Max Drawdown

-11.82% 1 Year

-22.45% 3 Years

-32.61% 5 Years

-37.84% 10 Years

Sharpe Ratio

1.41 1 Year

0.91 3 Years

0.17 5 Years

0.35 10 Years

Return Triangle (Heatmap)

Last updated: Nov 01, 2026

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2011	-7.2%	2.5%	18.3%	22.4%	17.6%	10.1%	11.4%	9.5%	10.5%	11.9%	10.9%	8.9%	8.5%	7.9%	8.8%
2012		13.2%	33.5%	34.2%	24.8%	13.9%	14.9%	12.2%	12.9%	14.3%	12.9%	10.5%	10.0%	9.1%	10.0%
2013			57.5%	46.2%	28.9%	14.1%	15.2%	12.0%	12.9%	14.4%	12.9%	10.2%	9.7%	8.8%	9.8%
2014				35.6%	16.6%	2.4%	6.5%	4.6%	6.8%	9.3%	8.3%	5.9%	5.8%	5.2%	6.6%
2015					0.3%	-11.0%	-1.7%	-1.9%	1.8%	5.4%	4.8%	2.7%	2.9%	2.6%	4.2%
2016						-20.9%	-2.7%	-2.7%	2.2%	6.5%	5.6%	3.0%	3.2%	2.8%	4.7%
2017							19.8%	8.0%	11.3%	14.7%	11.9%	7.7%	7.2%	6.2%	8.0%
2018								-2.6%	7.3%	13.1%	10.0%	5.4%	5.3%	4.4%	6.6%
2019									18.4%	21.9%	14.6%	7.5%	6.9%	5.7%	8.0%
2020										25.6%	12.7%	4.2%	4.3%	3.3%	6.3%
2021											1.2%	-5.1%	-2.0%	-1.6%	2.8%
2022												-11.1%	-3.6%	-2.5%	3.2%
2023													4.6%	2.0%	8.5%
2024														-0.4%	10.6%
2025															22.8%

Distributions

*by ETF Portfolio Weight Last updated: Nov 01, 2026

Profit Margin Distribution

< 0%

17%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

1y 3y N/A N/A

10 - 15%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

24%

1y 3y N/A N/A

30 - 40%

19%

1y 3y N/A N/A

> 40%

12%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

17%

1y 3y N/A N/A

0 - 10

11%

1y 3y N/A N/A

10 - 15

1y 3y N/A N/A

15 - 20

12%

1y 3y N/A N/A

20 - 25

1y 3y N/A N/A

25 - 35

21%

1y 3y N/A N/A

35 - 50

12%

1y 3y N/A N/A

> 50

21%

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

0.0%

1y 3y N/A N/A

Small Cap

11.6%

1y 3y N/A N/A

Mid Cap

24.0%

1y 3y N/A N/A

Large Cap

54.7%

1y 3y N/A N/A

Mega Cap

9.7%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Nov 08, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$29.1B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	0.36%	1.64%
Beta Indicates the relationship between the price performance of a share and the market.	0.75	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	117.49	22.61
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-20.86	-
Profitable Companies	64%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	131.91	9.45
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	6.95	3.37
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	6.15	6.33

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	23.86	14.02
Enterprise Value to Revenue Enterprise value divided by revenue	5.71	5.03
Total Debt to Enterprise Value Total debt divided by enterprise value	0.1	0.18
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	1.01	0.99
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	-16.56%	16.03%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-	+19.4%
Return on Equity Equity divided by market cap.	22.81%	24.21%
Return on Assets Indicates a company's profitability in relation to its total assets.	-4.99%	7.82%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	2.01%	13.87%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Regeneron Pharmaceuticals, Inc.

REGN - Manufacturing

Market Cap $97.44B

P/E Ratio 20.4

Dividends 0.4%

Total Investment $15.43M

Weight 5.47%

Loading details…

AMGEN Inc.

AMGN - Manufacturing

Market Cap $227.99B

P/E Ratio 26.8

Dividends 2.1%

Total Investment $14.72M

Weight 5.22%

Loading details…

Caredx Inc

CDNA - Health Care and Social Assistance

Market Cap $4.09B

P/E Ratio 31.3

Dividends 0.0%

Total Investment $14.21M

Weight 5.04%

Loading details…

Vertex Pharmaceuticals, Inc.

VRTX - Manufacturing

Market Cap $123.52B

P/E Ratio 34.4

Dividends 0.0%

Total Investment $14.06M

Weight 4.99%

Loading details…

Royalty Pharma plc - Ordinary Shares - Class A

RPRX - Manufacturing

Market Cap $30.86B

P/E Ratio 41.0

Dividends 1.4%

Total Investment $13.93M

Weight 4.94%

Loading details…

Biogen Inc

BIIB - Manufacturing

Market Cap $24.48B

P/E Ratio 107.4

Dividends 0.0%

Total Investment $13.5M

Weight 4.79%

Loading details…

Gilead Sciences, Inc.

GILD - Manufacturing

Market Cap $189.18B

P/E Ratio -54.2

Dividends 1.9%

Total Investment $12.5M

Weight 4.43%

Loading details…

United Therapeutics Corp

UTHR - Manufacturing

Market Cap $25.18B

P/E Ratio 20.7

Dividends 0.0%

Total Investment $11.49M

Weight 4.08%

Loading details…

Bio-Techne Corp

TECH - Manufacturing

Market Cap $11.44B

P/E Ratio 66.2

Dividends 0.5%

Total Investment $10.53M

Weight 3.73%

Loading details…

Illumina Inc

ILMN - Manufacturing

Market Cap $18.8B

P/E Ratio 35.1

Dividends 0.0%

Total Investment $9.89M

Weight 3.51%

Loading details…

Protagonist Therapeutics Inc

PTGX - Manufacturing

Market Cap $8.55B

P/E Ratio 25.4

Dividends 0.0%

Total Investment $9.57M

Weight 3.40%

Loading details…

Vericel Corp

VCEL - Manufacturing

Market Cap $2.91B

P/E Ratio 86.3

Dividends 0.0%

Total Investment $9.21M

Weight 3.27%

Loading details…

Alnylam Pharmaceuticals Inc

ALNY - Manufacturing

Market Cap $20.03B

P/E Ratio 8.1

Dividends 0.0%

Total Investment $8.93M

Weight 3.17%

Loading details…

Incyte Corp.

INCY - Professional, Scientific, and Technical Services

Market Cap $24.6B

P/E Ratio 57.6

Dividends 0.0%

Total Investment $8.62M

Weight 3.06%

Loading details…

Repligen Corp.

RGEN - Manufacturing

Market Cap $10.73B

P/E Ratio -799.0

Dividends 0.0%

Total Investment $8.57M

Weight 3.04%

Loading details…

Acadia Pharmaceuticals Inc

ACAD - Manufacturing

Market Cap $3.24B

P/E Ratio 8.8

Dividends 0.0%

Total Investment $8.52M

Weight 3.02%

Loading details…

Halozyme Therapeutics Inc.

HALO - Manufacturing

Market Cap $11.39B

P/E Ratio 23.9

Dividends 0.0%

Total Investment $8.41M

Weight 2.98%

Loading details…

Qiagen NV

QGEN - Manufacturing

Market Cap $9.35B

P/E Ratio 26.8

Dividends 5.3%

Total Investment $8.16M

Weight 2.89%

Loading details…

Biomarin Pharmaceutical Inc. - Registered Shares

BMRN - Manufacturing

Market Cap $9.86B

P/E Ratio -635.9

Dividends 0.0%

Total Investment $7.95M

Weight 2.82%

Loading details…

Neurocrine Biosciences, Inc.

NBIX - Manufacturing

Market Cap $16.97B

P/E Ratio 24.0

Dividends 0.0%

Total Investment $7.5M

Weight 2.66%

Loading details…

Manufacturing	86.7%
Health Care and Social Assistance	7.6%
Professional, Scientific, and Technical Services	5.7%

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

Allworth Financial LP Buys Shares of 2,530 Regeneron Pharmaceuticals, Inc. $REGN

Regeneron Pharmaceuticals, Inc. Notice of September 14, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

AMGEN Inc.

AMGEN Inc.

Caredx Inc

Caredx Inc

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Royalty Pharma plc - Ordinary Shares - Class A

Royalty Pharma plc - Ordinary Shares - Class A

Biogen Inc

Biogen Inc

Gilead Sciences, Inc.

Gilead Sciences, Inc.

United Therapeutics Corp

United Therapeutics Corp

Bio-Techne Corp

Bio-Techne Corp

Illumina Inc

Illumina Inc

Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

Vericel Corp

Vericel Corp

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Incyte Corp.

Incyte Corp.

Repligen Corp.

Repligen Corp.

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc

Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc.

Qiagen NV

Qiagen NV

Biomarin Pharmaceutical Inc. - Registered Shares

Biomarin Pharmaceutical Inc. - Registered Shares

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

Cookie Settings